Brightspec Announces $18.4 Million Financing Round Led By Genoa Ventures And Arboretum Ventures

Dec 14, 2022•over 2 years ago

Amount Raised

$18.4 Million

WalthamInformation Technology

Investors

Uva Seed FundMedvest CapitalArboretum VenturesGenoa Ventures

Description

BrightSpec, Inc., a life science tools company commercializing Molecular Rotational Resonance (MRR) spectroscopy, announced today the closing of an $18.4 million Series C financing round, led by Genoa Ventures and Arboretum Ventures. The round includes participation from existing investors including Medvest Capital, Felton Group LLC, and the UVA Seed Fund. Jenny Rooke, Ph.D., and Dan Kidle, from Genoa and Arboretum respectively, have joined BrightSpec's Board of Directors.

Company Information

Company

BrightSpec

Location

1466 Main St.

Waltham, Massachusetts, United States

About

BrightSpec, Inc. is the leading provider of Molecular Rotational Resonance (MRR) spectrometry solutions. Combining the structural power of NMR with the speed, accuracy, and precision of Mass Spectrometry, MRR provides comprehensive small molecule identification in a single instrument. Rapid, accurate results are obtained directly from complex samples by eliminating the need for chromatography. To date, BrightSpec has empowered customers with proven solutions across the pharmaceutical, consumer, and industrial chemical industries.

Related People

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends